Baidu
map

Lancet Infect Dis:疟疾疫苗RTS,S药效的汇总分析

2013-03-09 文馨 医学论坛网

  3月1日在线发表于《柳叶刀·传染病学》杂志(the Lancet Infectious Diseases)的一项针对个体参与者的汇总分析显示,RTS,S/AS01疫苗对抗疟疾的药效持续时间有限,疫苗注射3年后就检测不到了。而且,随着疟疾传播强度的增加,其药效减低。注射疫苗后的临床转归无法通过一项汇总分析来准确测量。然而,对于疫苗对公众健康转归的预测还需要考虑由于疾

  3月1日在线发表于《柳叶刀·传染病学》杂志(the Lancet Infectious Diseases)的一项针对个体参与者的汇总分析显示,RTS,S/AS01疫苗对抗疟疾的药效持续时间有限,疫苗注射3年后就检测不到了。而且,随着疟疾传播强度的增加,其药效减低。注射疫苗后的临床转归无法通过一项汇总分析来准确测量。然而,对于疫苗对公众健康转归的预测还需要考虑由于疾病传播强度的变化和注射疫苗后的时间长短。

原文链接: 

Bejon P, White MT, Olotu A, Bojang K, Lusingu JP, Salim N, Otsyula NN, Agnandji ST, Asante KP, Owusu-Agyei S, Abdulla S, Ghani AC.Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis. 2013 Feb 28. doi:pii: S1473-3099(13)70005-7.

Moorthy V, Newman R, Duclos P, Okwo-Bele J, Smith P.Assessment of the RTS,S/AS01 malaria vaccine. Lancet Infect Dis. 2013 Feb 28. doi:pii: S1473-3099(13)70047-1.



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1672282, encodeId=4d6c16e2282a1, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat Sep 14 17:07:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677364, encodeId=95d116e736453, content=<a href='/topic/show?id=a31ae044675' target=_blank style='color:#2F92EE;'>#疟疾疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70446, encryptionId=a31ae044675, topicName=疟疾疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=327a27492917, createdName=dongjia2019, createdTime=Wed Apr 24 13:07:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053569, encodeId=7917205356976, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Nov 17 18:07:00 CST 2013, time=2013-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011806, encodeId=130d201180670, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Sep 29 21:07:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827521, encodeId=a431182e52157, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 29 12:07:00 CST 2013, time=2013-03-29, status=1, ipAttribution=)]
    2013-09-14 lsndxfj
  2. [GetPortalCommentsPageByObjectIdResponse(id=1672282, encodeId=4d6c16e2282a1, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat Sep 14 17:07:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677364, encodeId=95d116e736453, content=<a href='/topic/show?id=a31ae044675' target=_blank style='color:#2F92EE;'>#疟疾疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70446, encryptionId=a31ae044675, topicName=疟疾疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=327a27492917, createdName=dongjia2019, createdTime=Wed Apr 24 13:07:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053569, encodeId=7917205356976, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Nov 17 18:07:00 CST 2013, time=2013-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011806, encodeId=130d201180670, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Sep 29 21:07:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827521, encodeId=a431182e52157, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 29 12:07:00 CST 2013, time=2013-03-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1672282, encodeId=4d6c16e2282a1, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat Sep 14 17:07:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677364, encodeId=95d116e736453, content=<a href='/topic/show?id=a31ae044675' target=_blank style='color:#2F92EE;'>#疟疾疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70446, encryptionId=a31ae044675, topicName=疟疾疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=327a27492917, createdName=dongjia2019, createdTime=Wed Apr 24 13:07:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053569, encodeId=7917205356976, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Nov 17 18:07:00 CST 2013, time=2013-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011806, encodeId=130d201180670, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Sep 29 21:07:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827521, encodeId=a431182e52157, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 29 12:07:00 CST 2013, time=2013-03-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1672282, encodeId=4d6c16e2282a1, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat Sep 14 17:07:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677364, encodeId=95d116e736453, content=<a href='/topic/show?id=a31ae044675' target=_blank style='color:#2F92EE;'>#疟疾疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70446, encryptionId=a31ae044675, topicName=疟疾疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=327a27492917, createdName=dongjia2019, createdTime=Wed Apr 24 13:07:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053569, encodeId=7917205356976, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Nov 17 18:07:00 CST 2013, time=2013-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011806, encodeId=130d201180670, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Sep 29 21:07:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827521, encodeId=a431182e52157, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 29 12:07:00 CST 2013, time=2013-03-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1672282, encodeId=4d6c16e2282a1, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat Sep 14 17:07:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677364, encodeId=95d116e736453, content=<a href='/topic/show?id=a31ae044675' target=_blank style='color:#2F92EE;'>#疟疾疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70446, encryptionId=a31ae044675, topicName=疟疾疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=327a27492917, createdName=dongjia2019, createdTime=Wed Apr 24 13:07:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053569, encodeId=7917205356976, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Nov 17 18:07:00 CST 2013, time=2013-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011806, encodeId=130d201180670, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Sep 29 21:07:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827521, encodeId=a431182e52157, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 29 12:07:00 CST 2013, time=2013-03-29, status=1, ipAttribution=)]
    2013-03-29 howi

相关资讯

PNAS:儿童抵御疟疾感染的分子机制

近日,来自Sainte-Justine大学医学中心和蒙特利尔大学的研究者发现了一些新型基因,这些新型基因可以使得儿童的免疫系统对疟疾感染产生更为有效的反应。相关研究成果刊登在近日的国际杂志PNAS上。该文章的作者进行世界范围内的疟疾研究已经长达13年时间了。 疟疾是世界范围内的主要健康问题,每年有超过30亿人群处于高风险阶段,有成千上然的人因为疟疾感染而死亡。 本文研究中,研究者使用了一种不同

J Med Chem:化合物ML267可抵抗疟疾

近日,来自加州大学的研究者首次报道了一种可以抑制引发疟疾的寄生虫关键酶的抑制剂,研究发现为我们开发抗疟疾药物提供了基础,相关研究成果刊登在了国际杂志Journal of Medicinal Chemistry上。 热带疟疾一年可造成超过120万人死亡,很多严重的疾病都是由恶性疟原虫引发,并且其可以通过按蚊在人类中传播。文章中研究者对350,000中化合物进行高通量筛选,有针对性的识别可以抑制寄生

亚太地区22亿人面临罹患疟疾风险

  世界卫生组织与遏制疟疾伙伴关系11月2日发布的一份最新报告显示,亚太地区共有近22亿人生活在受疟疾感染的阴影之下,2010年亚太地区共有约3000万个新发疟疾病例,由此导致的死亡人数超过4万2000人。   世卫组织和遏制疟疾伙伴关系在2日在澳大利亚悉尼举行的“疟疾2012大会”上发布了的名为《在亚洲、太平洋、美洲、中东和欧洲战胜疟疾》的报告阐述了疟疾对非洲以外国家的发展和卫生事业所造成的影

Nature:中药常山活性成分常山酮halofuginone作用机制被揭示

   常山为虎耳草科植物常山的根,是一种传统中药,千年以来一直被人们用于治疗疟疾相关的发热。现在Scripps研究所TSRI的博后周辉皓(Huihao Zhou音译)获得了常山活性成分的高分辨率结构,揭开了常山治疗疟疾的神秘机制。中药常山     常山的活性成分被称为常山酮halofuginone,是常山碱febrifugine的衍生物,对免疫系

Baidu
map
Baidu
map
Baidu
map